奥精医疗(688613) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥56,021,033.87, an increase of 16.54% compared to the same period last year[4] - Total profit for the quarter was ¥5,208,841.85, reflecting a significant increase of 294.96% year-over-year[4] - Net profit attributable to shareholders was ¥5,965,270.89, up 237.64% from the previous year[4] - Basic earnings per share for the quarter were ¥0.04, representing a 233.33% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2025 reached ¥156,057,979.41, an increase of 5.8% compared to ¥148,311,250.58 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was ¥10,595,768.44, a significant recovery from a net loss of ¥810,499.78 in the same period of 2024[22] - Earnings per share for the first three quarters of 2025 were ¥0.10, compared to ¥0.04 in the same period of 2024, indicating a 150% increase[23] - The total comprehensive income for the first three quarters of 2025 was ¥11,365,996.85, a recovery from a loss of ¥785,374.73 in the same period of 2024[23] Cash Flow - The cash flow from operating activities showed a negative net amount of ¥258,934.31, a deterioration of 97.68% compared to the same period last year[4] - Operating cash inflow totaled $199.65 million, up from $131.79 million year-over-year[27] - Cash outflow from operating activities was $204.15 million, compared to $152.38 million in the previous year[27] - Net cash flow from operating activities was -$4.50 million, an improvement from -$20.59 million year-over-year[27] - Cash inflow from investment activities was $25.04 million, down from $985.28 million in the previous year[27] - Cash outflow from investment activities totaled $47.97 million, compared to $974.45 million last year[27] - Net cash flow from investment activities was -$22.93 million, a decline from $10.83 million year-over-year[27] - Cash inflow from financing activities was $14.71 million, down from $23.54 million in the previous year[29] - Cash outflow from financing activities was $6.46 million, compared to $15.05 million last year[29] - Net cash flow from financing activities was $8.24 million, slightly down from $8.49 million year-over-year[29] - The ending cash and cash equivalents balance was $137.94 million, down from $159.99 million at the end of the previous year[29] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥1,544,836,085.14, a slight increase of 0.37% from the end of the previous year[5] - The total current assets as of September 30, 2025, amounted to RMB 1,215,045,444.13, showing an increase from RMB 1,196,396,879.83 as of December 31, 2024, representing a growth of approximately 1.5%[17] - Total liabilities decreased to ¥96,058,675.71 in 2025 from ¥119,200,213.96 in 2024, showing a reduction of approximately 19.4%[20] - Owner's equity attributable to shareholders increased to ¥1,435,033,515.43 in 2025 from ¥1,402,874,383.57 in 2024, reflecting a growth of 2.3%[20] - Total assets reached RMB 1,544,836,085.14, slightly up from RMB 1,539,163,337.61, showing a marginal increase of approximately 0.4%[18] Research and Development - Research and development expenses totaled ¥11,722,614.67, accounting for 20.93% of operating revenue, an increase of 4.69 percentage points year-over-year[5] - Research and development expenses for the first three quarters of 2025 were ¥27,453,429.72, compared to ¥24,366,528.85 in 2024, marking an increase of 12.8%[21] Shareholder Information - The company reported a total of 9,862 common shareholders at the end of the reporting period[12] - The top shareholder, HU ERIC GANG, holds 9,487,066 shares, representing 6.92% of the total shares[12] Operational Issues - The company has not reported any significant changes in shareholder relationships or financing activities during the reporting period[14] - There are no applicable audit opinions for the financial statements as they are unaudited[15] - The company has not identified any other significant operational issues during the reporting period[15] Other Income - The company reported a significant increase in other income, totaling ¥2,853,312.23 in 2025 compared to ¥293,569.96 in 2024[22] Inventory and Receivables - Accounts receivable decreased to RMB 57,562,253.96 from RMB 67,159,276.75, a decline of about 14%[17] - Inventory increased significantly to RMB 85,598,891.55 from RMB 54,577,004.67, representing an increase of approximately 56.9%[18]